December 30, 2024

Nutrafol Safety Signal Emerges in Case Study

A previously healthy 26-year-old developed severe liver injury after using Nutrafol, with a biopsy confirming marked necroinflammatory damage with complete resolution upon discontinuation.

Conexiant

December 23, 2024

Cancer Drug Side Effect Causes Skin Changes

New research reveals that one-third of cancer patients developed red, inflammatory skin lesions before experiencing vitiligo-like depigmentation from immune checkpoint inhibitor therapy, potentially offering clinicians an early warning sign.

Conexiant

December 19, 2024

Comparing CBT Delivery Methods in Atopic Dermatitis

A new study published in JAMA Dermatology reveals that a self-guided online cognitive behavioral therapy program for atopic dermatitis was noninferior to clinician-guided treatment, offering promise for disseminating evidence-based psychological treatment for patients.

Conexiant

December 13, 2024

Researchers Target 2035 for Psoriasis Cure

A recent paper in the Journal of Investigative Dermatology discusses the potential of a cure for psoriasis through early therapeutic intervention and a personalized medicine approach.

Conexiant

December 13, 2024

Large Study Reveals Melanoma's Hidden Risks

Analysis of over 280,000 melanoma patients reveals these survivors face significantly elevated risks of developing 12 different types of second primary cancers, with the risk being particularly pronounced in younger patients and those with thicker tumors.

Conexiant

December 12, 2024

Key Genetic Variants in Palmoplantar Keratoderma

In a Danish cohort of 142 patients with palmoplantar keratoderma, researchers identified DSP variants linked to cardiomyopathy risk in seemingly typical cases, highlighting why genetic testing matters beyond just diagnosis.

Conexiant

December 12, 2024

Phase 3 Data: Nemolizumab for Prurigo Nodularis Relief

A recent study published in JAMA Dermatology revealed the significant efficacy of nemolizumab in reducing pruritus and skin lesions in patients with moderate to severe prurigo nodularis.

Conexiant

December 10, 2024

ASCVD Risk Elevated in Cutaneous Lupus

Recent study in JAMA Dermatology shows patients with cutaneous lupus erythematosus have a 72% higher risk of developing atherosclerotic cardiovascular disease, emphasizing the need for targeted screening and management.

Conexiant

December 09, 2024

Reduced Infection Rates with Long-Term Dupilumab in Kids

A recent study reveals that dupilumab can reduce infection rates in young children with moderate-to-severe atopic dermatitis, offering potential long-term benefits for this patient population.

Conexiant